Drug Trial News

RSS
Orexigen, Takeda announce FDA's issue of complete response letter for Contrave NDA

Orexigen, Takeda announce FDA's issue of complete response letter for Contrave NDA

1 Feb 2011
Discovery Labs provides expanded update on efforts to gain FDA marketing authorization for Surfaxin in RDS

Discovery Labs provides expanded update on efforts to gain FDA marketing authorization for Surfaxin in RDS

1 Feb 2011
AVEO commences enrollment in tivozanib Phase 2 study in renal cell carcinoma

AVEO commences enrollment in tivozanib Phase 2 study in renal cell carcinoma

1 Feb 2011
Circassia Phase II clinical trial confirms safety profile of ToleroMune cat allergy treatment

Circassia Phase II clinical trial confirms safety profile of ToleroMune cat allergy treatment

1 Feb 2011
Highly favorable final results from ERGOFLEX initial clinical study for joint pain relief

Highly favorable final results from ERGOFLEX initial clinical study for joint pain relief

1 Feb 2011
Positive results from NRM8499 phase I clinical study in patients with Alzheimer's disease

Positive results from NRM8499 phase I clinical study in patients with Alzheimer's disease

1 Feb 2011
FDA grants Onyx fast track designation for carfilzomib in treatment of relapsed and refractory multiple myeloma

FDA grants Onyx fast track designation for carfilzomib in treatment of relapsed and refractory multiple myeloma

1 Feb 2011
VBL commences two studies to evaluate efficacy, safety of VB-111 in advanced cancers

VBL commences two studies to evaluate efficacy, safety of VB-111 in advanced cancers

31 Jan 2011
Maxygen initiates Phase I study to evaluate CTLA4-Ig therapeutic for treatment of rheumatoid arthritis

Maxygen initiates Phase I study to evaluate CTLA4-Ig therapeutic for treatment of rheumatoid arthritis

31 Jan 2011
GATTEX Phase 3 pivotal study reaches primary efficacy endpoint of reducing PN in patients with SBS

GATTEX Phase 3 pivotal study reaches primary efficacy endpoint of reducing PN in patients with SBS

31 Jan 2011
Scientists to commence new DNA vaccine trial for use in patients with leukemia

Scientists to commence new DNA vaccine trial for use in patients with leukemia

31 Jan 2011
Cohort Review Committee evaluates SCIB1 dose escalation, safety in Phase 1 trial

Cohort Review Committee evaluates SCIB1 dose escalation, safety in Phase 1 trial

31 Jan 2011
Phase III study shows tapentadol ER relieves chronic pain associated with DPN

Phase III study shows tapentadol ER relieves chronic pain associated with DPN

29 Jan 2011
Tarceva Phase III EURTAC study in NSCLC patients with EGFR activating mutations meets primary endpoint

Tarceva Phase III EURTAC study in NSCLC patients with EGFR activating mutations meets primary endpoint

28 Jan 2011
Phase II trial finds fostamatinib ineffective in RA patients not responsive to biologic agents

Phase II trial finds fostamatinib ineffective in RA patients not responsive to biologic agents

28 Jan 2011
Cetero Research completes 20,000th early-phase clinical study

Cetero Research completes 20,000th early-phase clinical study

28 Jan 2011
Arena reduces workforce by 25% and provides update on lorcaserin

Arena reduces workforce by 25% and provides update on lorcaserin

28 Jan 2011
Interim results from ganetespib Phase 2 trial in NSCLC to be presented at 11th IASLC annual meeting

Interim results from ganetespib Phase 2 trial in NSCLC to be presented at 11th IASLC annual meeting

28 Jan 2011
Receptos begins RPC1063 Phase 1 clinical study in patients with multiple sclerosis

Receptos begins RPC1063 Phase 1 clinical study in patients with multiple sclerosis

28 Jan 2011
Iniparib Phase III study in metastatic triple-negative breast cancer does not meet primary goal

Iniparib Phase III study in metastatic triple-negative breast cancer does not meet primary goal

28 Jan 2011

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback